Company Quick10K Filing
Green Planet Bio Engineering
10-K 2020-12-31 Filed 2021-03-31
10-Q 2020-09-30 Filed 2020-11-13
10-Q 2020-06-30 Filed 2020-08-14
10-Q 2020-03-31 Filed 2020-05-15
10-K 2019-12-31 Filed 2020-03-11
10-Q 2019-09-30 Filed 2019-11-08
10-Q 2019-06-30 Filed 2019-08-12
10-Q 2019-03-31 Filed 2019-05-08
10-K 2018-12-31 Filed 2019-03-01
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-10
10-Q 2018-03-31 Filed 2018-05-11
10-K 2017-12-31 Filed 2018-03-08
10-Q 2017-09-30 Filed 2017-10-27
10-Q 2017-06-30 Filed 2017-08-04
10-Q 2017-03-31 Filed 2017-05-15
10-K 2016-12-31 Filed 2017-03-10
10-Q 2016-09-30 Filed 2016-11-04
10-Q 2016-06-30 Filed 2016-08-09
10-Q 2016-03-31 Filed 2016-05-13
10-K 2015-12-31 Filed 2016-03-30
10-Q 2015-09-30 Filed 2015-11-16
10-Q 2015-06-30 Filed 2015-08-11
10-Q 2015-03-31 Filed 2015-05-14
10-K 2014-12-31 Filed 2015-03-31
10-Q 2014-09-30 Filed 2014-11-14
10-Q 2014-06-30 Filed 2014-08-15
10-Q 2014-03-31 Filed 2014-05-15
10-K 2013-12-31 Filed 2014-04-15
10-Q 2013-09-30 Filed 2013-11-14
10-Q 2013-06-30 Filed 2013-08-16
10-Q 2013-03-31 Filed 2013-05-20
10-K 2012-12-31 Filed 2013-04-16
10-Q 2012-09-30 Filed 2012-11-14
10-Q 2012-06-30 Filed 2012-08-20
10-Q 2012-03-31 Filed 2012-05-14
10-K 2011-12-30 Filed 2012-04-03
10-Q 2011-09-30 Filed 2011-11-21
10-Q 2011-06-30 Filed 2011-08-15
10-Q 2011-03-31 Filed 2011-05-16
10-K 2010-12-31 Filed 2011-04-14
10-Q 2010-09-30 Filed 2010-11-10
10-Q 2010-06-30 Filed 2010-08-23
10-Q 2010-03-31 Filed 2010-05-17
10-K 2009-12-31 Filed 2010-03-30
8-K 2019-12-18

GPLB 10K Annual Report

EX-31.1 gplb_311.htm
EX-31.2 gplb_ex312.htm
EX-32 gplb_ex32.htm

Green Planet Bio Engineering Earnings 2020-12-31

Balance SheetIncome StatementCash Flow

10-K 1 gplb_10k.htm ANNUAL REPORT gplb_10k
 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_______________________
 
FORM 10-K
_______________________
(Mark One)
 
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Fiscal Year Ended December 31, 2020
or
 
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from              to       
      
Commission file number 000-52622
GREEN PLANET BIOENGINEERING CO., LTD.
(Exact Name of Registrant as Specified in its charter)
 
 Delaware
 37-1532842
 (State or Other Jurisdiction of Incorporation or organization)
 (I.R.S. Employer Identification No.)
 
                  20807 Biscayne Blvd., Suite 203,  Aventura, Florida
 33180
 (Address of Principal Executive Offices)
 (Zip Code)
 
Registrant’s Telephone Number, Including Area Code: (786) 279-2900
 
Securities registered pursuant to Section 12(b) of the Act:    NONE
 
Securities registered pursuant to Section 12(g) of the Act:  NONE
 
Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes      No  
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.    Yes  ☐    No  ☒
 
Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ☐
 
Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer
 ☐
Accelerated filer
 ☐
Non-accelerated filer
 ☐
Smaller reporting company
 ☒
(Do not check if a smaller reporting company)
 
 
 
 
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☒  No  ☐
 
The aggregate market value of the registrant’s common stock held by non-affiliates was $39,393 based on the closing sale price of common stock on June 30, 2020. The number of shares of common stock outstanding as of March 31, 2021 was 20,006,402.
 

 
 
 
TABLE OF CONTENTS
 
 
 
 
 
 
 
Business
4
Risk Factors
4
Unresolved Staff Comments
5
Properties
5
Legal Proceedings
5
Mine Safety Disclosures
5
 
 
 
 
 

 
 
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer
 
Purchases of Equity Securities
6
Selected Financial Data
6
Management’s Discussion and Analysis of Financial Condition and Results of Operations
6
Quantitative and Qualitative Disclosures about Market Risk
7
Financial Statements
7
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
16
Controls and Procedures
16
Other Information
16
 
 
 
 
 
 
 
 
Directors, Executive Officers and Corporate Governance
17
Executive Compensation
18
Security Ownership of Certain Beneficial Owners and Management and Related
 
 
Stockholder Matters
18
Certain Relationships and Related Transactions, and Director Independence
18
Principal Accounting Fees and Services
18
 
 
 18
PART IV
 
 
 
 
 
Exhibits and Financial Statement Schedules
19
 
 
 
Signatures
 20
 
 
 
 
 FORWARD-LOOKING STATEMENTS
 
This Annual Report on Form 10-K contains forward-looking statements. These statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses. Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,” “believes,” “may,” “will,” “should,” “could,” “plans,” “estimates,” and similar language or negative of such terms. Our actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we do not know whether we can achieve positive future results, levels of activity, performance, or goals. Actual events or results may differ materially. We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances taking place after the date of this document.
 
 
 
 
PART I
 
ITEM 1.    BUSINESS
 
Description of Business
 
Green Planet Bioengineering Co., Ltd. (“Green Planet” or “Company”) operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation.
 
Our History
 
Mondo Acquisition II, Inc. was incorporated in the State of Delaware on October 30, 2006 and changed the name to Green Planet Bioengineering Co., Ltd. on October 2, 2008. In October 2008, the Company acquired Elevated Throne Overseas Ltd, a company incorporated in British Virgin Islands, and its subsidiaries (“Elevated Throne”) which operated the business in the agritech sector in the People’s Republic of China. The Company divested Elevated Throne to One Bio, Corp. (“ONE”) on April 14, 2010.
 
In March 2012, Global Funds Holdings Corp. (“Global Funds”) an Ontario, Canada corporation became a majority stockholder of the Company.
 
The Company operates as a public organized shell corporation with the purpose to acquire or merge with an existing business operation. The Company’s activities are subject to significant risks and uncertainties, as their ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities.
 
ITEM 1A. RISK FACTORS
 
You should consider carefully each of the following business and investment risk factors and all of the other information in this report. If any of the following risks and uncertainties develops into actual events, the business, financial condition or results of our operations could be materially and adversely affected. If that happens, the trading price of our shares of common stock could decline significantly. The risk factors below contain forward-looking statements regarding our business. Actual results could differ materially from those set forth in the forward-looking statements. See "Special Note Regarding Forward-Looking Information."
 
Risk Related to the Covid-19 pandemic
 
The Company’s operation has not been materially and adversely impacted by the Covid-19 pandemic. While the Company is able to continue operations as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation that can operate with some of the staff working from home and minimal staff at the office as long as they maintain social distancing. Until this stay at home order is lifted the Company will continue to follow social distancing order. The Company is unable to predict the impact of the Covid-19 pandemic at this time.
 
Risk Related to the Company's Future Business
 
We give no assurances that any plans for future business will be implemented if we do not secure adequate financing or find profitable business opportunities.
 
Our ability to implement and execute our future business plans and ultimately generate enough business revenue is directly influenced by our ability to secure adequate financing or find profitable business opportunities. If we do not receive funding from future investors or find profitable business opportunities, we will experience delays in our business plans and, ultimately, in our profitability going forward.
 
We will continue to incur significant costs as a result of remaining as a public reorganized company, and management will be required to devote substantial time to new compliance requirements.
 
As a public company, we incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act of 2002, together with rules implemented by the Securities and Exchange Commission and applicable market regulators. These rules impose various requirements on public companies, including requiring certain corporate governance practices. Management and other personnel will need to devote a substantial amount of time to these new compliance requirements. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costlier.
 
In addition, the Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations and testing of our internal controls over financial reporting to allow management and our registered independent public accounting firm to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our testing, or the subsequent testing by our registered independent public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. Compliance with Section 404 may require that we incur substantial accounting expenses and expend significant management efforts. If we are not able to comply with the requirements of Section 404 in a timely manner, or if our registered independent accountants later identify deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other applicable regulatory authorities.
 
 
4
 
 
Risks Related to the Common Stock
 
There is currently no trading market for our common stock.
Outstanding shares of our common stock cannot be offered, sold, pledged or otherwise transferred unless subsequently registered pursuant to, or exempt from registration under, the Securities Act and any other applicable federal or state securities laws or regulations. These restrictions will limit the ability of our stockholders to liquidate their investment.
 
We have not paid and do not anticipate paying any dividends on our common stock; therefore, our securities could face devaluation in the market.
 
We have paid no dividends on our common stock to date and it is not anticipated that any dividends will be paid to holders of our common stock in the foreseeable future. While our dividend policy will be based on the operating results and capital needs of the business, it is anticipated that any earnings will be retained to finance our future expansion and for the implementation of our new business plan. Lack of a dividend can further affect the market value of our common stock, and could significantly affect the value of any investment in us.
 
Penny Stock Regulations
 
The SEC has adopted regulations which generally define "penny stock" to be an equity security that has a market price of less than $5.00 per share. Our common stock, when and if a trading market develops, may fall within the definition of penny stock and subject to rules that impose additional sales practice requirements on broker-dealers.
 
For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of such securities and have received the purchaser's prior written consent to the transaction. Additionally, for any transaction, other than exempt transactions, involving a penny stock, the rules require the delivery, prior to the transaction, of a risk disclosure document mandated by the Securities and Exchange Commission relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer's presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. Consequently, the "penny stock" rules may restrict the ability of broker-dealers to sell our common stock and may affect the ability of investors to sell their common stock in the secondary market.
 
ITEM 1B.    UNRESOLVED STAFF COMMENTS
 
None
 
ITEM 2.    PROPERTIES
 
None
 
ITEM 3.    LEGAL PROCEEDINGS
 
None
 
ITEM 4.    MINE SAFETY DISCLOSURES
 
None
 
 
5
 
 
PART II
 
ITEM 5.    MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
 
The Company’s common stock is available for quotation on the Over the Counter Bulletin Board under the symbol “GPLB.PK.” There is no assurance that the company’s stock will continue to be quoted or that any liquidity will exist for our stockholders.
 
The following table shows, for each quarter of fiscal 2020 and 2019 the high and low closing price per share of common stock as reported on the Over the Counter Bulletin Board. The following quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions. The source of this information is NASDAQ Over the Counter Bulletin Board Research Report.
 
 
 
 2020 
 
 
 2019 
 
 Quarter Ended
 
  High
 
 
  Low
 
 
  High
 
 
  Low
 
 Fourth Quarter
 $0.060 
 $0.041 
 $0.055 
 $0.040 
 Third Quarter
  0.118 
  0.050 
  0.055 
  0.032 
 Second Quarter
  0.118 
  0.040 
  0.050 
  0.032 
   First Quarter
  0.080 
  0.040 
  0.180 
  0.045 
 
We have never declared or paid any cash dividends on our common stock.
 
ITEM 6.    SELECTED FINANCIAL DATA
 
Not applicable.
 
ITEM 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTSOF OPERATIONS
 
Overview
 
The Company operates as a public reorganized corporation with the business purpose to acquire or merge with an existing business operation.
 
Results of Operations
 
The Company did not have any operations and did not have any operating revenues during the years ended December 31, 2020 and 2019, respectively.
 
Total expenses for the for the years ended December 31, 2020 and 2019 were $33,599 and $25,358, respectively. The majority of these expenses primarily constituted administrative expenses related to accounting and compliance with the Exchange Act.
 
Liquidity and Capital Resources
 
The Company had no active business operation during the year. Accordingly, all the Company’s cash flow needs for 2020 were provided solely by a related party of Global Funds to pay expenses necessary as a public company.
 
Going forward, the Company will continue to source adequate funding from future investors to execute business opportunities when they arise in the future. However, such funding and business opportunities will rely entirely on the prevailing circumstances when the funding or profitable business opportunities are identified. If such opportunities are not identified in the near term, the Company will experience delay in effecting its business plans.
 
The financial statements have been prepared assuming that the Company will continue as a going concern. The Company is currently a public reorganized shell corporation and has no current business activity. The Company’s ability to continue as a going concern is dependent on continued support from a related party of Global Funds, the majority stockholder. This gives rise to substantial doubt about the Company’s ability to continue as a going concern.
 
 
6
 
 
Critical Accounting Policies and Estimates
 
We prepare our financial statements in conformity with accounting principles generally accepted (“GAAP”) in the United States of America. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon historical experience, current trends and other factors. As such, actual results could differ from our estimates and such differences could be material. We have identified below the critical accounting policies which are assumptions made by management about matters that are uncertain and are of critical importance in the presentation of our financial position, results of operations and cash flows. On a regular basis, we review our accounting policies and how they are applied and disclosed in the financial statements.
 
The preparation of financial statements in conformity with GAAP in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
 
Off-Balance Sheet Arrangements
 
There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
 
ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
None
 
ITEM 8.    FINANCIAL STATEMENTS
 
INDEX TO FINANCIAL STATEMENTS
 
Report of Independent Registered Public Accounting Firm
8
Financial Statements:
 
Balance Sheets
 9
Statements of Operations
 10
Statements of Cash Flows
 11
Statements of Changes in Stockholders’ Deficit
 12
Notes to the Financial Statements
 13-15
 
 
 
7
 
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
To the Board of Directors and Stockholders of:
Green Planet Bioengineering Co., Ltd.
 
Opinion on the Financial Statements
 
We have audited the accompanying balance sheets of Green Planet Bioengineering Co., Ltd. (the Company) as of December 31, 2020 and 2019, and the related statements of income, stockholders’ deficit, and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019 and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America.
 
Going Concern
 
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company is currently a public reorganized shell corporation and has no current business activity. The Company’s ability to continue as a going concern is dependent on continued support from a related party. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans concerning these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty
 
Basis for Opinion
 
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
 
/s/ Liggett & Webb, P.A.
LIGGETT & WEBB, P.A
Certified Public Accountants
We have served as the Company’s auditor since 2019
 
Boynton Beach, Florida
March 31, 2021
 
 
 
 
8
 
 
Green Planet Bioengineering Co., Ltd
Balance Sheets
(Stated in US Dollars)
 
 
 
December 31, 2020
 
 
December 31, 2019
 
 
 
 
 
 
 
 
ASSETS
 
 
 
 
 
 
Current assets
 $- 
 $- 
Cash and cash equivalents
 $- 
 $- 
 
    
    
TOTAL CURRENT ASSETS
    
    
 
    
    
LIABILITIES AND STOCKHOLDERS’ DEFICIT
    
    
 
    
    
LIABILITIES
    
    
Current liabilities
    
    
Accounts payable
 $- 
 $214 
Amount due to a related party
  316,458 
  282,645 
 
    
    
TOTAL CURRENT LIABILITIES
  316,458 
  282,859 
 
    
 

 
COMMITMENTS AND CONTINGENCIES
    
    
 
    
    
STOCKHOLDERS’ DEFICIT
    
    
Preferred stock: par value of $0.001 per share
    
    
Authorized: 10,000,000 shares at December 31, 2020 and December 31, 2019
    
    
Issued and outstanding:
    
    
None at December 31, 2020 and December 31, 2019
   
   
 
    
    
Common stock: par value of $0.001 per share
    
    
Authorized: 250,000,000 shares at December 31, 2020 and December 31, 2019
    
  - 
Issued and outstanding: 20,006,402 shares at December 31, 2020 and December 31, 2019
  20,006 
  20,006  
Additional paid-in-capital
  609,614 
  609,614  
Accumulated deficit
  (946,078)
  (912,479)
 
    
    
TOTAL STOCKHOLDERS’ DEFICIT
  (316,458)
  (282,859
 
    
    
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
 $- 
 $- 
 
See Notes to the Financial Statements
 
 
9
 
 
Green Planet Bioengineering Co., Ltd
Statements of Operations
(Stated in US Dollars)
 
 
  Years ended December 31,      
 
 
2020
 
 
2019
 
Administrative expenses
 $(33,599)
 $(25,358)
 
    
    
Loss before income tax
  (33,599)
  (25,358)
Provision for income taxes
  - 
  - 
 
    
    
Net loss
 $(33,599)
 $(25,358)
 
    
    
Loss per share
    
    
-Basic and diluted
 $(*) 
 $(*) 
 
    
    
Weighted average number of shares outstanding
    
    
-Basic and diluted
  20,006,402  
  20,006,402 
 
*
  Less than $.01, per share
 
See Notes to the Financial Statements
 
 
10
 
 
Green Planet Bioengineering Co., Ltd
Statements of Cash Flows
(Stated in US Dollars)
 
 
  Years ended December 31,      
 
 
2020
 
 
2019
 
Cash flows from operating activities
 
 
 
 
 
 
Net loss
 $(33,599)
 $(25,358)
Changes in operating assets and liabilities:
    
    
Accounts payable
  (214)
  214 
Accrued liabilities
  - 
  (11,750)
 
    
    
Net cash flows used in operating activities
  (33,813)
  (36,894)
 
    
    
Cash flows from financing activities
    
    
Amount due to a related party
  33,813 
  36,894 
 
    
    
Net cash flows provided by financing activities
  33,813 
  36,894 
 
    
    
Net decrease in cash and cash equivalents
  - 
  - 
 
    
    
Cash and cash equivalents – beginning of year
  - 
  - 
 
    
    
Cash and cash equivalents – end of year
 $- 
 $- 
 
    
    
Supplemental disclosures for cash flow information:
    
    
Cash paid for interest
 $- 
 $- 
Cash paid for income taxes
 $- 
 $- 
 
See Notes to the Financial Statements
 
 
11
 
 
Green Planet Bioengineering Co., Ltd
Statements of Changes in Stockholders’ Deficit
(Stated in US Dollars)
 
 
 
Preferred Stock
 
 
 Common Stock  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Number of shares
 
 
  Amount
 
 Number of shares
 
 Amount
 
 Additional paid-in capital
 
 Accumulated deficit
 
 Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance, December 31, 2018
  - 
 $- 
  20,006,402 
 $20,006 
 $609,614 
 $(887,121)
 $(257,501)
 
    
    
    
    
    
    
    
Net loss
  - 
  - 
  - 
  - 
  - 
  (25,358)
  (25,358)
 
    
    
    
    
    
    
    
 
    
    
    
    
    
    
    
Balance, December 31, 2019
  - 
    
  20,006,402 
 $20,006 
 $609,614 
 $(917,479)
 $(282,859)
 
    
    
    
    
    
    
    
Net Loss
  - 
  - 
  - 
  - 
  - 
  (33,599)
  (33,599)
 
    
    
    
    
    
    
    
Balance, December 31, 2020
  - 
 $- 
  20,006,402 
 $20,006 
 $609,614 
 $(946,078)
 $(316,458)
 
See Notes to the Financial Statements
 
 
12
 
 
Green Planet Bioengineering Co., Ltd.
Notes to the Financial Statements
1. General Information
 
Mondo Acquisition II, Inc. was incorporated in the State of Delaware on October 30, 2006 and the name was changed to Green Planet Bioengineering Co., Ltd. (“Company”) on October 2, 2008. In October 2008, the Company acquired Elevated Throne Overseas Ltd, incorporated in British Virgin Islands, and its subsidiaries (“Elevated Throne”) and operated the business in the agritech sector in the People’s Republic of China. The Company divested Elevated Throne to One Bio, Corp. (“ONE”) on April 14, 2010.
 
In March 2012, Global Funds Holdings Corp. (“Global Funds”) an Ontario, Canada corporation became a majority stockholder of the Company.
 
The Company operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation.   The Company's activities are subject to significant risks and uncertainties, as their ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities. 
 
2. Summary of Significant Accounting Policies
 
Basis of Presentation
The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).
 
Use of Estimates
The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported. Actual results could differ from those estimates. Significant items that require estimates were accruals of liabilities.
 
Cash and Cash Equivalents
Cash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents. Balances of cash and cash equivalents in financial institutions may at times exceed the government-insured limits.
 
Income Taxes
The Company accounts for income taxes in accordance with FASB ASC Topic 740 “Income Taxes” under which deferred tax assets and liabilities are determined based on temporary differences between accounting and tax bases of assets and liabilities and net operating loss and credit carry forwards, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. A provision for income tax expense is recognized for income taxes payable for the current period, plus the net changes in deferred tax amounts. Any interest and penalties are expensed in the year that the Notice of Assessment is received. The Company’s practice is to recognize interest and/or penalties related to income tax matters as interest expense.
 
Loss Per Share
Earnings per share is reported in accordance with FASB ASC Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2020 and 2019, the Company does not have any common share equivalents outstanding.
  
 
13
 
 
2. Summary of Significant Accounting Policies – continued
 
Fair Value Measurements
FASB ASC Topic 820, “Fair Value Measurements and Disclosures” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investments measured and reported at fair value are classified and disclosed in one of the following hierarchy:
 
Level 1 - 
Quoted prices are available in active markets for identical investments as of the period reporting date.
Level 2 - 
Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.
Level 3 - 
Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require significant management judgment or estimation.
 
Recent Changes in Accounting Standards
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The standard will modify the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. ASU No. 2018-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period. Early adoption is permitted upon issuance of this ASU. The Company is permitted to early adopt any removed or modified disclosures upon issuance of this ASU and delay adoption of the additional disclosures until their effective date. The adoption of this ASU did not have a material impact on the Company’s financial statements.
 
In June 2018, the FASB issued ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The changes take effect for public companies for fiscal years starting after December 15, 2018, including the interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material impact on the Company’s financial statements.
 
Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.
 
3. Going Concern
 
The financial statements have been prepared assuming that the Company will continue as a going concern. The Company is currently a public reorganized shell corporation and has no current business activity. The Company’s ability to continue as a going concern is dependent on continued support from a related party. This gives rise to substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that may result from the outcome of this uncertainty. 
 
4. Amount Due to a Related party
 
The Company relies on a related party to advance funds to fund its operating expenses. As of December 31, 2020 and 2019, the amounts advanced of $316,458 and $282,645 respectively are interest-free, unsecured and are repayable upon demand.
 
In addition, the Chief Executive Officer, Chief Financial Officer and Director of the Company is also a director of the related party.
 
 
14
 
 
5. Preferred Stock/Common Stock
 
Series A preferred stock
The Company is authorized under its Articles of Incorporation to issue 10,000,000 shares of Series A preferred stock with a par value of $0.001 per share. Each share of the Company’s preferred stock provides the holder with the right to vote 1,000 votes on all matters submitted to a vote of the stockholders of the Company and is convertible into 1,000 shares of the Company’s common stock. The preferred stock is non-participating and carries no dividend. The Company does not have any issued shares of the preferred stock as of December 31, 2020 and 2019.
 
Common Stock
The Company is authorized to issue 250,000,000 shares of common stock with a par value of $0.001 per share. During the year ended December 31, 2020, the Company did not issue any shares of common stock or warrants.
 
6. Income Tax
 
As of December 31, 2020, the Company had net operating loss carry forwards of approximately $910,000 that may be available to reduce future years’ taxable income through 2037 for approximately $876,000 and indefinitely for $34,000. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The deferred tax asset and valuation allowance were reduced by approximately $1,000 to reflect the change in the federal tax rate from 34% to 21%.
 
The provision for Federal income tax consists of the following for the years ended December 31, 2020 and December 31, 2019:
 
 
 
 December 31, 2020
 
 
 December 31, 2019
 
 Federal income tax benefit attributable to:
 
 
 
 
 
 
 Net loss
 $(8,500)
 $(6,400)
 Change in tax estimates
  10,200 
  - 
 Less: valuation allowance
  (1,700)
  6,400 
  
    
    
 Net provision for Federal income taxes
 $- 
 $- 
 
The cumulative tax effect at the expected rate of 21% for 2020 and 21% for 2019 of significant items comprising our net deferred tax amount is as follows as of December 31, 2020 and December 31, 2019:
 
 
 
  December 31,2020
 
 
 December 31, 2019
 
 Deferred tax asset attributable to:
 $231,000 
 $232,000 
 Net operating loss carry forwards
  (231,000)
  (232,000)
 Less: valuation allowance
    
    
 
    
    
 Net deferred tax asset
 $- 
 $- 
 
Due to the change in ownership in March 2012, the net operating loss carry forwards as of December 31, 2011 of $213,844 may be subject to limitations in accordance with Sec 382 of the provisions of the Tax Reform Act of 1986 for Federal income tax purposes. Tax return for the years ended December 31, 2020, 2019 and 2018 remain open to and it by Federal and State Tax Authorities.
  
 
15
 
 
ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None
 
ITEM 9A.    CONTROLS AND PROCEDURES
 
Disclosure Control and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in company reports filed or submitted under the Securities Exchange Act of 1934, or the “Exchange Act,” is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our chief executive officer as appropriate to allow timely decisions regarding disclosure.
 
The Company’s management, with the participation of the Company’s President and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the financial year end. Based upon their evaluation, the Company’s President and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective and did not note any material weakness.
 
Management’s Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate “internal control over financial reporting” as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:
 
i.
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
 
ii.
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
 
iii.
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.
 
As of December 31, 2020, and as reported in the Registrant’s Form 10-K filing, management used the framework set forth in the report entitled “Internal Control – Integrated Framework” published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management concluded that at December 31, 2020 there were no material weakness and concluded that the internal control over financial reporting was effective. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
 
During the year, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect, our internal control over financial reporting.
 
ITEM 9B. OTHER INFORMATION
 
None
 
 
16
 
 
PART III
 
ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
 
Generally, each of our directors is elected to a term of one year and serves until his or her successor is elected and qualified. The Directors and Officers of the Company are as follows:
 
Name
Age
Position
Term
Jordan Weingarten
31
President and Director
March 2012 to present
 
Mr. Weingarten graduated from York University with a degree in business administration. He is an executive with experience in financial controls, finance and global management. Amongst other assignments, Mr. Weingarten was financial control specialist at Trade Finance Solutions, Inc, a Canadian corporation, and was also involved in management at a global Polaroid Licensee. Mr. Weingarten also worked with international wholesalers and distributors of electronics and various other products. Based in Miami, Florida, Mr. Weingarten brings knowledge and experience of global economics, finances and cultural environment. The President & Director of Green Planet Bioengineering Co. Ltd. is also a Director of the Related Party.
 
All of our directors hold offices until the next annual meeting of the stockholders of the Company, and until their successors have been qualified after being elected or appointed.  Officers serve at the discretion of the Board of Directors.
 
Director Compensation
We do not currently nor have we ever compensated our directors.
 
Involvement in Legal Proceedings
None of our executive officers or directors have been the subject of any order, judgment, or decree of any court of competent jurisdiction, or any regulatory agency permanently or temporarily enjoining, barring suspending or otherwise limiting him from acting as an investment advisor, underwriter, broker or dealer in the securities industry, or as an affiliated person, director or employee of an investment company, bank, savings and loan association, or insurance company, or from engaging in or continuing any conduct or practice in connection with any such activity or in connection with the purchase or sale of any securities.
 
None of our executive officers or directors has been convicted in any criminal proceeding (excluding traffic violations) or is the subject of a criminal proceeding that is currently pending.
 
None of our executive officers or directors is the subject of any material pending legal proceeding.
 
Audit Committee
The Company has not as of yet established an audit committee. The Board of Directors currently serves as the Company’s audit committee.
 
Compensation Committee
The Company has not as of yet established a compensation committee. The Board of Directors currently serves as the Company’s compensation committee.
 
Section 16 (A) Beneficial Ownership Reporting Compliance
Section 16 (A) of the Securities Exchange Act of 1934, as amended, requires the Company’s directors, executive officers and persons who own more than 10% of a class of the Company’s equity securities which are registered under the Exchange Act to file with the Securities and Exchange Commission initial reports of ownership and reports of changes of ownership of such registered securities. Such executive officers, directors and greater than 10% beneficial owners are required by Commission regulation to furnish the Company with copies of all Section 16 (A) forms filed by such reporting persons.
 
To the Company’s knowledge, based solely on a review of the copies of such reports furnished to the Company and on representations that no other reports were required, no person required to file such a report, failed to file during fiscal 2020 and 2019.
 
Code of Ethics
The Board of Directors adopted a Code of Ethics in April 2009, meeting the requirements of Section 406 of the Sarbanes-Oxley Act of 2002. The Company will provide to any person without charge, upon request, a copy of such Code of Ethics.
 
 
17
 
 
ITEM 11.    EXECUTIVE COMPENSATION
 
The Company did not pay any compensation to its executive officers for the years ended December 31, 2011 to 2020.
 
ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
 
 
 Shares of Common Stock Beneficially Owned (1) 
 
 Name of Beneficial Owner
 
 
 Number
 
 
 
      % (2)
 
 Global Funds Holdings Corp
  18,508,733 
  92 
______________________________________________________________________________________________________
 
(1) 
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Shares of common stock subject to securities anticipated to be exercisable or convertible at or within 60 days of the date hereof, are deemed outstanding for computing the percentage of the person holding such option or warrant but are not deemed outstanding for computing the percentage of any other person. The indication herein that shares are anticipated to be beneficially owned is not an admission on the part of the listed stockholder that he, she or it is or will be a direct or indirect beneficial owner of those shares.
 
(2) 
Based upon 20,006,402 shares of common stock issued and outstanding as of December 31, 2020.
 
ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
Certain Relationships
None
 
Related Transactions
All related transactions have been reported in Part II Item 8 Financial Statements.
 
ITEM 14.    PRINCIPAL ACCOUNTING FEES AND SERVICES
 
Audit Fees
The aggregate fees billed for fiscal year ended December 31, 2020 and 2019 for professional services rendered by Liggett and Webb P.A. for the audit of the Company’s annual financial statements was $10,000 and $10,000 respectively.
 
The aggregate fees billed for fiscal year ended December 31, 2020 for professional services rendered by Liggett and Webb P.A. and 2019 services rendered by Schulman Lobel, LLP for the reviews of the Company’s quarterly financial statements included in the Company’s Form 10-Q’s was $15,000 and $15,000 respectively.
 
Audit Related Fees
None
 
Tax Fees
Tax fees are those fees billed for professional services rendered for tax compliance, including preparation of corporate federal and state income tax returns, tax advice and tax planning. For the years ended December 31, 2020 and 2019, no tax fees were billed by Liggett & Webb, P.A.
 
 
18
 
 
All Other Fees
None
 
Policy for Pre-Approval of Audit and Non-Audit Services
 
We have not established an audit committee. Our board of directors approved the services rendered and fees charged by our independent registered public accounting firm.
 
Our board of directors’ policy is to pre-approve all audit services and all non-audit services that our independent registered public accounting firm is permitted to perform for us under applicable federal securities regulations. As permitted by the applicable regulations, our board of directors’ policy utilizes a combination of specific pre-approval on a case-by-case basis of individual engagements of the independent registered public accounting firm.
 
All engagements of the independent registered public accounting firm to perform any audit services and non-audit services since that date have been pre-approved by our board of directors in accordance with the pre-approval policy. The policy has not been waived in any instance. All engagements of the independent registered public accounting firm to perform any audit services and non-audit services prior to the date the pre-approval policy was implemented were approved by our board of directors in accordance with its normal functions.

ITEM 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
 
(a) Exhibits
 
31.1          
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2          
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32          
Certification pursuant to 18 U.S.C. Section 1350
 
 
 
19
 
 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized this 31st day of March, 2021.
 
 
Green Planet Bioengineering Co., Ltd
 
By: /s/ Jordan Weingarten
_________________________________
Jordan Weingarten
President (Principal Executive Officer
and Principal Financial and Accounting
Officer) and Director
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
 
 
 
Date: March 31, 2021                                                                    By: /s/ Jordan Weingarten
Jordan Weingarten
President and Director

 
20